ANTIHISTAMINE ACTIVITY, CENTRAL-NERVOUS-SYSTEM AND CARDIOVASCULAR PROFILES OF HISTAMINE H-1 ANTAGONISTS - COMPARATIVE-STUDIES WITH LORATADINE, TERFENADINE AND SEDATING ANTIHISTAMINES IN GUINEA-PIGS

被引:36
作者
HEY, JA
DELPRADO, M
CUSS, FM
EGAN, RW
SHERWOOD, J
LIN, CC
KREUTNER, W
机构
[1] Schering-Plough Research Institute, Kenilworth, NJ 07033-0539
关键词
TORSADES DE POINTES; ANTIHISTAMINE; SEDATION; NONSEDATING ANTIHISTAMINE; CARDIOTOXICITY; ELECTROCARDIOGRAM; ELECTROENCEPHALOGRAM;
D O I
10.1111/j.1365-2222.1995.tb00400.x
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background Sedation limits the clinical utility of classical H-1 antihistamines, while newer antihistamines such as loratadine and terfenadine are non-sedating. However, clinical use of terfenadine has been associated with rare but severe cardiac arrhythmias, in particular torsades de pointes. Objective To establish a quantitative experimental model for assessing the sedating and cardiotoxicity potential of non-sedating and sedating antihistamines. Methods Drugs were administered intravenously and the integrated amplitude of the cortical electroencephalogram (EEG) signal was recorded. The threshold dose that depressed EEG activity was compared with the dose required to inhibit by 50% the peripheral bronchospasm elicited by 10 mu g/kg i.v., of histamine. In separate studies, the electrocardiogram (ECG) and cardiovascular effects of loratadine (30 and 100 mg/kg, i.v.), terfenadine (10 mg/kg, i.v.), promethazine (5 mg/kg, i.v.) and diphenhydramine (20 mg/kg, i.v.) were evaluated. Results The sedating antihistamines, diphenhydramine and promethazine, depressed the integrated EEG at doses between 0.6 and 2.0 times their peripheral antihistamine doses. Loratadine had no EEG depressant activity al 100 mg/kg, i.v., a dose more than 170 times its ED50 (0.58 mg/kg, i.v.) against histamine bronchospasm We were unable to evaluate the EEG effects of terfenadine, because it produced cardiovascular collapse at 10 mg/kg, i.v. Loratadine and promethanine did not produce adverse cardiovascular effects, nor did they alter normal ECG activity. Diphenhydramine produced bradycardia followed by a transient hypertensive phase without affecting the QTc interval. In contrast, terfenadine elicited hypotension, bradycardia and significant arrhythmogenic activity, causing a prolongation of the QTc interval and a torsades de pointes - like ventricular arrhythmia. Pharmacokinetic studies after i.v. administration of loratadine (30 and 100 mg/kg) demonstrated plasma levels of loratadine and its major metabolite descarboethoxyloratadine to be several orders of magnitude greater than levels found in humans at the clinical dose of 10 mg. Conclusion The CNS depressant effects of H-1 antihistamines are promethazine approximate to diphenhydramine much greater than loratadine = placebo. Of the non-sedating antihistamines, loratadine was devoid of adverse cardiovascular effects whereas terfenadine caused a pronounced disruption of the normal ECG, characterized by a torsades de pointes-like effect.
引用
收藏
页码:974 / 984
页数:11
相关论文
共 27 条
[1]   EVALUATION OF THE CNS PROPERTIES OF SCH-29851, A POTENTIAL NON-SEDATING ANTIHISTAMINE [J].
BARNETT, A ;
IORIO, LC ;
KREUTNER, W ;
TOZZI, S ;
AHN, HS ;
GULBENKIAN, A .
AGENTS AND ACTIONS, 1984, 14 (5-6) :590-597
[2]  
Bazett HC, 1920, HEART-J STUD CIRC, V7, P353
[3]   THE QT INTERVAL AND DRUG-ASSOCIATED TORSADES-DE-POINTES [J].
BENEDICT, CR .
DRUG INVESTIGATION, 1993, 5 (01) :69-79
[4]  
BROWNLEE KA, 1965, STATISTICAL THEORY M, P346
[5]   BENZO-1,4-OXAZEPIN-5-ONES AND PYRIDO-1,4-OXAZEPIN-5-ONES AND PYRIDO-1,4-OXAZEPIN-5-THIONES - SYNTHESIS AND STRUCTURE-ACTIVITY-RELATIONSHIPS OF A NEW SERIES OF H-1 ANTIHISTAMINES [J].
CALE, AD ;
GERO, TW ;
WALKER, KR ;
LO, YS ;
WELSTEAD, WJ ;
JAQUES, LW ;
JOHNSON, AF ;
LEONARD, CA ;
NOLAN, JC ;
JOHNSON, DN .
JOURNAL OF MEDICINAL CHEMISTRY, 1989, 32 (09) :2178-2199
[6]   LORATADINE - A PRELIMINARY REVIEW OF ITS PHARMACODYNAMIC PROPERTIES AND THERAPEUTIC EFFICACY [J].
CLISSOLD, SP ;
SORKIN, EM ;
GOA, KL .
DRUGS, 1989, 37 (01) :42-57
[7]  
DOUGLAS WW, 1970, PHARMACOL BASIS THER, P635
[8]   H-1-RECEPTOR ANTAGONISTS - COMPARATIVE TOLERABILITY AND SAFETY [J].
ESTELLE, F ;
SIMONS, R .
DRUG SAFETY, 1994, 10 (05) :350-380
[9]  
GOLDSTEIN L, 1986, J CLIN PHARMACOL, V8, P42
[10]   PHARMACOKINETICS AND DOSE PROPORTIONALITY OF LORATADINE [J].
HILBERT, J ;
RADWANSKI, E ;
WEGLEIN, R ;
LUC, V ;
PERENTESIS, G ;
SYMCHOWICZ, S ;
ZAMPAGLIONE, N .
JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 27 (09) :694-698